Mitochondrial complex I deficiency Cell Models for Research

Mitochondrial complex I deficiency is the most common mitochondrial disorder, with an estimated prevalence of 1 in 5,000 live births (WHO, 2023). It presents with a wide spectrum of clinical phenotypes, including Leigh syndrome, MELAS, and hypertrophic cardiomyopathy, often leading to early mortality. The 5-year survival rate for severe infantile-onset forms is less than 20% (NCI, 2023). The disease is caused by mutations in nuclear or mitochondrial genes encoding complex I subunits, with over 40 genes implicated. The clinical heterogeneity and lack of effective therapies underscore the urgent need for research models.

Complex I deficiency is an ideal model for studying mitochondrial dysfunction, oxidative stress, and energy metabolism. Its genetic heterogeneity allows for investigation of genotype-phenotype correlations. Public datasets, such as those from the Mitochondrial Disease Sequence Data Resource (MSeqDR) and ClinVar, provide extensive variant information. Open questions include the role of specific mutations in disease progression and the development of targeted therapies. Gene-edited cell models enable precise manipulation of these mutations to dissect molecular mechanisms.

• • Complex I deficiency disrupts the mitochondrial electron transport chain, leading to reduced ATP production and increased reactive oxygen species (ROS). Key pathways include:
• • Oxidative phosphorylation (OXPHOS): Impaired proton pumping and electron transfer.
• • ROS production: Elevated ROS cause oxidative damage to lipids, proteins, and DNA.
• • Apoptosis: Mitochondrial dysfunction triggers intrinsic apoptotic pathways.
• • Mitophagy: Impaired clearance of damaged mitochondria exacerbates cellular stress.

Data from TCGA and COSMIC.

• • Complex I deficiency affects multiple signaling networks:
• • AMPK pathway: Activated in response to low ATP, promoting catabolism.
• • mTOR pathway: Suppressed due to energy stress, affecting cell growth.
• • NF-κB pathway: Activated by ROS, leading to inflammation.
• • HIF-1α pathway: Stabilized under oxidative stress, influencing metabolism.
• • Calcium signaling: Altered due to mitochondrial dysfunction.

Organoids derived from patient iPSCs offer a more physiologically relevant model, recapitulating tissue-specific mitochondrial dysfunction.

• • Animal models include:
• • Patient-derived xenografts (PDX): Not common for mitochondrial diseases due to metabolic differences.
• • Genetically engineered mouse models (GEMM): Knock-in of Ndufs4 or Ndufs6 mutations recapitulates Leigh syndrome.
• • Induced models: Chemical inhibitors like rotenone or piericidin A induce complex I deficiency.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific complex I mutations. For example, a NDUFS7 knockout line can be generated to study loss-of-function effects, while a knock-in line with a pathogenic MT-ND4 mutation can model patient-specific variants. These models are sequence-verified and commercially available, accelerating research by providing consistent and reproducible systems. They are essential for drug screening and functional validation.

Knockout and knock-in lines are used to validate the function of genes involved in complex I deficiency. For instance, NDUFS7 knockout in HEK293 cells confirms its role in complex I assembly and activity. Knock-in of a pathogenic MT-ND4 mutation in SH-SY5Y cells allows study of mitochondrial dysfunction in a neuronal context.

Isogenic pairs (wild-type vs. mutant) are used in high-throughput screens to identify compounds that rescue complex I activity. For example, screening a library of FDA-approved drugs in a NDUFS7 knockout line can identify potential therapeutic agents. Resistance mechanisms can be studied by exposing cells to increasing concentrations of mitochondrial toxins.

CRISPR synthetic lethality screens can identify genes that are essential only in complex I-deficient cells, revealing potential drug targets. For example, a screen in a MT-ND4 mutant line may identify a kinase whose inhibition selectively kills mutant cells, providing a biomarker for patient stratification.